Tackling Antibiotic Resistance by Bloom, Gerry
In today’s world, drug resistant infections travel and spread as quickly as planes do. 
Therefore it is in the UK’s interest to tackle AMR and to help other countries to do the 
same. Priority actions including investing in Universal Health Coverage and resilient 
health systems in developing countries, tackling counterfeit drugs and also antibiotic use 
within animal health and agricultural. This is an issue the UK has an opportunity to be a 
global leader on, to foster the critical international partnerships between governments, 
the private sector and civil society that will be necessary to solve the AMR crisis long-term.
In 2015 the WHO Director General characterised the global challenge of antimicrobial resistance (AMR), which 
includes antibiotic resistance, as: ‘threatening the very core of medicine and the sustainability of an effective 
global public health response to the enduring threat of infectious diseases’. The World Bank estimates that if 
AMR remains unchecked, global domestic product per annum will be decreased by up to 3.8 per cent by 2050. 
A global approach to a global problem - 
with the UK taking a leading role
• Addressing the urgent problem of AMR requires an 
integrated, global approach that recognises the 
different priorities of developing and developed 
countries.  
• Developing new drugs, diagnostics or monitoring 
and restricting drug use alone will not be enough to 
tackle the problem.  Investing in Universal Health 
Coverage and resilient health systems around the 
world is also essential to ensure that people have 
access to effective treatment of common infectious 
diseases, as is the need to simultaneously address 
counterfeit drugs and antibiotic use within animal 
health and the agricultural industry.  
• The UK has an opportunity to be a global leader on 
this issue and build on the work being led by Professor Dame Sally Davies and the Department of Health, 
to foster the critical international partnerships between governments, the private sector and civil society 
that will be necessary to solve the crisis long-term. 
• Countries with larger national incomes and higher levels of economic and social organisation have a stake 
in the success of measures by relatively low-income countries to reduce the risk infectious diseases and 
increase access to effective treatment.
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What is Antimicrobial Resistance 
(AMR)?
Antimicrobial resistance occurs when  
microorganisms that cause illness such 
as viruses, bacteria or parasites mutate 
after contact with antimicrobial drugs, 
which include antibiotics, antifungals and 
antimalarials in to so-called ‘super bugs’. 
It leads to drugs we have relied on for 
decades being rendered ineffective and 
risks infections spreading within the body 
and infectious diseases spreading to other 
people.   
It is estimated that more 
than 25,000 patients die 
annually in the EU due 
to multidrug-resistance 
(MDR in bacterial  
infections, ECDC/EMEA 
Joint Working Group, 
2009. The bacterial  
challenge: time to react)
480,000
Globally, 480,000  
people develop  
multi-drug resistant 
TB each year, and drug 
resistance is starting to 
complicate the fight 
against HIV and malaria, 
as well. 
(WHO)
25,000
•    Addressing the urgent problem of AMR requires an integrated, global approach 
that recognises the different priorities of developing and developed countries.  “
“
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Universal Health Coverage 
• More focus is needed on solving basic health problems through investment in universal 
health coverage. The overuse of antibiotics may not be a priority for developing countries 
where their populations are still dying from diseases that are easily treatable.  
• The risk of emergence and subsequent transmission of AMR genes can be reduced by 
immunising the population against common infectious diseases; reducing exposure to 
infections through contaminated water and food and reducing susceptibility to 
infections by improving nutrition.
Recommendations for UK policy makers 
• Invest UKaid in building resilient health systems in developing countries in order to make 
progress towards both Universal Health Coverage and addressing AMR.  
• To protect UK citizens, the UK government should take the lead in forging international 
partnerships between government, scientists and pharmaceutical companies, which will 
be needed in the future to agree the controlled and appropriate use of antibiotics. 
• Take a coherent, cross-government approach that includes Department of Health, 
Department for Internationa Development and the Foreign and Commonwealth Office 
to tackle AMR.
• Take a One Health approach to AMR. This means recognising that human, animal and 
environmental health are inter-related and so a multi-sectoral, interdisciplinary approach 
to prevention and mitigation of health crises is required. Monitoring and restricting 
antibiotic use in animals in agriculture, as well as in the treatment of people, is essential.
• There are no blueprints for implementing the significant and complex changes at the 
scale that is required to tackle AMR globally. It is therefore important to take an approach 
of continual feedback and learning along the way to establish best practice. 
• Measures to address AMR will need to be built on the foundation of strong regional 
and global agreements on actions that address the concerns of all countries and all social 
groups. 
• National action plans need to take into account regional and global interdependencies. 
Dense transportation links, the movement of large quantities of goods and people, the 
behaviour of international pharmaceutical companies and international media influence 
national systems.
•    Invest UKaid in building resilient health systems in developing 
countries in order to make progress towards both Universal Health 
Coverage and addressing AMR.  
“ “
